FR2621818A1 - MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION - Google Patents

MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION Download PDF

Info

Publication number
FR2621818A1
FR2621818A1 FR8714346A FR8714346A FR2621818A1 FR 2621818 A1 FR2621818 A1 FR 2621818A1 FR 8714346 A FR8714346 A FR 8714346A FR 8714346 A FR8714346 A FR 8714346A FR 2621818 A1 FR2621818 A1 FR 2621818A1
Authority
FR
France
Prior art keywords
nasal
precise
spraying
dispensed
amphotericin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8714346A
Other languages
French (fr)
Other versions
FR2621818B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medipro
Original Assignee
Medipro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipro filed Critical Medipro
Priority to FR8714346A priority Critical patent/FR2621818B1/en
Priority to AU26248/88A priority patent/AU2624888A/en
Priority to PCT/FR1988/000512 priority patent/WO1989003672A1/en
Publication of FR2621818A1 publication Critical patent/FR2621818A1/en
Application granted granted Critical
Publication of FR2621818B1 publication Critical patent/FR2621818B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, netilmycin and amphotericin B, administered by precise spraying in the nasal and oropharyngeal cavities either in the form of a pressurized aerosol dispensed by a continuous or dosing valve or in the form of a nasal spray dispensed by a precise pump. Two pushers are provided with each bottle: one having a long thin cannula for introduction into the nostrils and spraying of the nasal fossae, the other having a cannula permetting generous spraying of the oropharyngeal cavity. The drug has a wide range of indications in all patients at risk of contracting a gram-negative bacillary infection or a mycosis.

Description

lut ente Invention (concerne un médicament pour vaporise+zon destinëL prévenir leS risques d'infection criez les malades à risques en décontaminant e cd'vités nasales et oropharyngées. lut ente Invention (concerns a medicine for spray + zone intended to prevent the risks of infection shout out patients at risk by decontaminating their nasal and oropharyngeal guests.

Les infections à bacilles gram négatif et les mycoses sont fréquentes chez 3e malades à risques . Elles entralnent une morbidité importante , elles sont une des' causes principales du décès de ces patients , elles augmentent les dépenses de santé en augmentant les durées d'hospitalisation
La présente invention permet de remédier à cet inconvénient . Elle comporte l'association de trois antibiotiques administrée par vaporisation dans les cavités nasales et orophryngées . Les trois antibiotiques associés dans la préparation sont la polymyxine B , la netilmitine et l'amphotéricine B .La préparation doit adhérer aux muqueuses nasales et buccales , relarguer lentement les antibiotiques et avoir une tension superficielle permettant un talenient maximal sur les muqueuses nasales et oropharyngées . La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise . Deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fosses nasales , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée .Infections with gram-negative bacilli and yeast infections are frequent in 3rd patients at risk. They cause significant morbidity, they are one of the 'main causes of death of these patients, they increase healthcare costs by increasing the length of hospital stays
The present invention overcomes this drawback. It involves the combination of three antibiotics administered by spraying into the nasal and orophryngeal cavities. The three antibiotics associated in the preparation are polymyxin B, netilmitine and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum talenient on the nasal and oropharyngeal mucous membranes. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and vaporization of the nasal cavities, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity.

Les doses distribuées par les valves ou les pompes seront tres précises
Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation
La fréquence des applications dépend également de la concentration de ces produits.The doses distributed by the valves or the pumps will be very precise
They are of course a function of the concentration of antibiotics within the preparation
The frequency of applications also depends on the concentration of these products.

Aucun de ces antibiotiques n'étant absorbé par voie nasale , oropharyngée ou digestive , les posologies et donc les concentrations peuvent varier dans une très large part
Les caractéristiques et avantages de l'invention ressortent de la description qui va suivre à titre d'exemple : pour 30 ml de préparation , on associe
-sulfate de polymyxine B : 500 mg -sulfate de nétilmi cine : 450 450 mg
-amphotéricine B : 2500 mg
-alcool à 900 : 1 ml
-saccharinate de sodium : 100 mg
-essence de menthe : 0,02ml
-glycérine : quantité suffisante pour 30 ml
La valve ou la pompe doit hêtre adaptée pour délivrer 0,5 ml à chaque preF- slow. . On recommande 6 pressions dans la cavité oropharyngée , 3 pressions dans chaque narine à chaque administration et une fréquence de quatre administrations par jour . Dans cet exemple , on administre 400 mg de polymyxine b ,360 mg de nétilmicine et 2000 mg d' amphotéricine B par jour
Ilest recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par sonde gastrique avec ces mêmes antibiotiques.None of these antibiotics being absorbed via the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
The characteristics and advantages of the invention appear from the description which follows by way of example: for 30 ml of preparation, one associates
- polymyxin B sulfate: 500 mg - netilmi cine sulfate: 450 450 mg
-amphotericin B: 2500 mg
- 900 alcohol: 1 ml
-sodium saccharinate: 100 mg
-mint essence: 0.02ml
-glycerin: sufficient quantity for 30 ml
The valve or pump must be suitable for delivering 0.5 ml for each pre-slow. . We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril with each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin b, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily
It is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by gastric tube with these same antibiotics.

Les indications de ce médicament sont très larges : ildoit être employé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent: en réanimation , en hématologie , en chirurgie ,en anesthésiologie , en cancérologie , etc...  The indications for this drug are very broad: it must be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc ...

Claims (4)

REVENDICATIONS 1) Médicament destiné à prévenir les risques d'infections à bacilles gram négatif caractérisé en ce qu'il comporte l'association de trois antibiotiques : polymyxine B , nétilmi cine et amphotéricine B administrée par vaporisation dans les cavités nasales et oropharyngées  1) Medication intended to prevent the risks of infections with gram-negative bacilli, characterized in that it comprises the combination of three antibiotics: polymyxin B, netilmi cine and amphotericin B administered by vaporization in the nasal and oropharyngeal cavities 2) Médicament selon la revendication 1 caractérisé en ce que la préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue qu doseuse soit sous forme de nébulisation distribuée par une pompe précise 2) Medicament according to claim 1 characterized in that the preparation is administered by precise spraying either in the form of pressurized aerosol dispensed by a continuous valve that doser is in the form of nebulization dispensed by a precise pump 3) Médicament selon la revendication 1 ou la revendication 2 caractérisé en ce que les doses distribuées par les valves oules pompes sont très précises 3) Medicament according to claim 1 or claim 2 characterized in that the doses dispensed by the valves or the pumps are very precise 4) Médicament selon l'une quelconque des revendications précédentes ca caractérisé en ce que deux poussoirs sont fournis avec chaque flacon : : l'un disposant d'une canule longue et fine permettant l'introduction par les narines , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée  4) Medicament according to any one of the preceding claims, characterized in that two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils, the other with a cannula allowing wide vaporization of the oropharyngeal cavity
FR8714346A 1987-10-19 1987-10-19 MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION Expired - Lifetime FR2621818B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR8714346A FR2621818B1 (en) 1987-10-19 1987-10-19 MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION
AU26248/88A AU2624888A (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying
PCT/FR1988/000512 WO1989003672A1 (en) 1987-10-19 1988-10-19 Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8714346A FR2621818B1 (en) 1987-10-19 1987-10-19 MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION

Publications (2)

Publication Number Publication Date
FR2621818A1 true FR2621818A1 (en) 1989-04-21
FR2621818B1 FR2621818B1 (en) 1990-12-14

Family

ID=9355911

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8714346A Expired - Lifetime FR2621818B1 (en) 1987-10-19 1987-10-19 MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION

Country Status (3)

Country Link
AU (1) AU2624888A (en)
FR (1) FR2621818B1 (en)
WO (1) WO1989003672A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440391C1 (en) * 1994-11-11 1996-05-09 Haider Angelika Use of aminoglycosides for the diagnosis of barrier disorders
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239B1 (en) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalant apparatus and atomizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5715640B2 (en) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
EP2694220B1 (en) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
BR112016023932B1 (en) 2014-05-07 2022-11-29 Boehringer Ingelheim International Gmbh NEBULIZER
HUE055604T2 (en) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Nebulizer
JP6580070B2 (en) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Container, nebulizer, and use
RU2605263C1 (en) * 2015-11-05 2016-12-20 государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL121455C (en) * 1900-01-01
GB1018125A (en) * 1962-11-29 1966-01-26 Merck & Co Inc Chemical products
AU539563B2 (en) * 1981-01-21 1984-10-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Primycin, doxycyline and sisomicin composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Merck Index", édition 10, 1983, pages 85,929,1093, Merck & Co., Inc., Rahway, NJ, US *

Also Published As

Publication number Publication date
AU2624888A (en) 1989-05-23
WO1989003672A1 (en) 1989-05-05
FR2621818B1 (en) 1990-12-14

Similar Documents

Publication Publication Date Title
FR2621818A1 (en) MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION
FR2621817A1 (en) DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
FR2624015A1 (en) MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
ES2330415T3 (en) SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS.
KR900012591A (en) Delivery device for oral administration
KR880013586A (en) Dosage device comprising a removable substrate with a solid state property
CA2039456A1 (en) Osmotic dosage system for liquid drug delivery
KR880002502A (en) Formulations for Administration of Beneficial Acid Sensitive Agents
DE69001812T2 (en) SYSTEM FOR PARENTERAL ADMINISTRATION OF AN ACTIVE SUBSTANCE.
ES2104522T3 (en) NEW MEDICINAL ADMINISTRATION SYSTEM.
WO2000018447A3 (en) Multiplex drug delivery system suitable for oral administration
DK0998916T3 (en) Medicines for administration to the mucosa
US4876283A (en) Antisnoring agent
DK0652744T3 (en) Pharmaceutical agents for delivering peptides through the mucosa
PT2101730E (en) Galenic form for the transmucosal delivery of paracetamol
BE900749A (en) MICROENCAPSULE DRUG IN A SWEET MATRIX.
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
CA1223210A (en) Antisnoring agent
KR970032872A (en) Drugs for the treatment of skin damage containing acetylsalicylic acid
WO2001008662A1 (en) Liquid pharmaceutical composition based on paracetamol
JP2002068963A (en) Liquid agent and container
FR2624017A1 (en) Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation
FR2622113A1 (en) Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation
FR2624738A1 (en) Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation
FR2624739A1 (en) Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation

Legal Events

Date Code Title Description
ST Notification of lapse